The benefits of Micronized Purified Flavonoid Fraction (MPFF) throughout the progression of Chronic Venous Disease (CVD)

At the 2019 European Venous Forum in Zurich Switzerland, a symposium entitled "State of the art: benefits of Micronized Purified Flavonoid Fraction (MPFF) throughout Chronic Venous Disease (CVD) progression" was held to discuss the developing treatment strategies for patients at all stages of Chronic Venous Disease (CVD).

At the early stages of Chronic Venous Disease (CVD), management should be focused on preventing disease progression through lifestyle changes and conservative treatment; treatment can also include venoactive drugs (VAD) such as Micronized Purified Flavonoid Fraction (MPFF), which is the most well-known and most widely prescribed venoactive drugs in Europe.

As the disease progresses, patients who require interventional procedures (e.g., endovenous procedure or sclerotherapy) can also benefit fromMicronized Purified Flavonoid Fraction (MPFF) treatment in the recovery period after the procedure, as Micronized Purified Flavonoid Fraction (MPFF) has been shown to reduce periprocedural pain and bleeding (hematoma), and to improve Chronic Venous Disease (CVD) symptoms during this period. Management of Chronic Venous Disease (CVD) in patients with venous leg ulcers (VLU) is the most challenging; in these patients, recommended adjunct therapies to be combined with standard compression therapy include VAD (MPFF) and non-VAD drugs (pentoxifylline and sulodexide) which have been shown to speed venous leg ulcers healing in comparison with compression therapy alone

Source: Andrew N Nicolaides, 2020 Feb;37(Suppl 1):1-5. doi: 10.1007/s12325-019-01218-8. Epub 2020 Jan 22.

SCAC 06/22 DM 165 DAF - For the exclusive use of the healthcare professional.